China Approves AstraZeneca's Tagrisso-Chemotherapy Combo Regime For Previously Untreated Lung Cancer Patients
Portfolio Pulse from Vandana Singh
China has approved AstraZeneca's Tagrisso combined with chemotherapy for first-line treatment of certain lung cancer patients. This approval follows similar approval in Japan and is based on positive results from the FLAURA2 Phase 3 trial, showing significant improvement in progression-free survival.
June 26, 2024 | 2:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
China's approval of AstraZeneca's Tagrisso combined with chemotherapy for first-line treatment of certain lung cancer patients is a significant regulatory milestone. The approval is based on positive results from the FLAURA2 Phase 3 trial, which showed a substantial improvement in progression-free survival. This follows a similar approval in Japan, indicating strong international support for the treatment.
The approval in China, following Japan, for Tagrisso combined with chemotherapy is a major regulatory achievement for AstraZeneca. The FLAURA2 Phase 3 trial results show a significant improvement in progression-free survival, which is likely to boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100